MNKD reports Q1 2026 results on the same day it announced a new dry powder inhalation program for Ralinepag — a partnership with United Therapeutics — giving the stock two live catalysts to absorb at once.
The options market is leaning hard into the bullish side of that equation. The put/call ratio has dropped to 0.33, nearly two standard deviations below its 20-day average of 0.41 — one of the most call-heavy readings of the past year. That kind of options tilt usually signals traders loading up on upside exposure rather than hedging against a miss. The contrast with the February earnings reaction is stark: after Q4 2025 results, the stock fell 6.3% the next day and shed 19% across the following five sessions. This time, the options crowd appears positioned for a different outcome.
Short interest tells a more complicated story. Bears have been adding meaningfully since late March, with SI rising from roughly 8% of the float to nearly 10% — a 22% build month-on-month. That level, close to 30 million shares short, is material for a small-cap biotech. This week, though, the pressure has started to ease: SI dropped about 3% on Tuesday alone, pulling back from a peak above 10.2% earlier this month. The borrow market is not flashing distress — cost to borrow is just 0.53%, a modest 14% tick higher on the week, and availability remains ample, meaning there is no imminent squeeze dynamic in the lending pool. The ORTEX short score of 55.9, while elevated, has actually eased from 57.6 at the start of the week.
The Street is meaningfully more bullish than the stock price would suggest. The analyst consensus mean target is $6.94 — more than double the current close of $2.86. Wells Fargo raised its target to $8 last week while keeping its Overweight rating, a positive signal fresh enough to carry weight. Most other firms have been trimming targets since the February miss: Mizuho cut from $10 to $8 in mid-April, and RBC downgraded to Sector Perform back in late February after slashing its target from $7.50 to $3.50. Bulls point to Tyvaso DPI royalty growth, label updates, and the expanding IPF/PPH pipeline as the path to $150M in annual revenue. Bears flag competitive pressure — notably Boehringer Ingelheim's Jascayd approval — and ongoing patent risk. Today's Ralinepag DPI announcement, developed specifically for United Therapeutics, adds a pipeline dimension that wasn't in the February conversation.
Inside the company, the signal is mixed but tilts constructive at the top. CEO Michael Castagna bought 100,000 shares at $2.59 in March — with the stock now at $2.86, he's in the money — though he had been selling heavily in December at prices above $5.50. CFO Christopher Prentiss sold a small block in late April at $2.74, worth just $34,000, which reads more like routine compensation-plan activity than a directional statement. On the institutional side, State Street added nearly 4 million shares as recently as April 30 — a notable addition relative to its existing position — while BlackRock and Vanguard both made smaller incremental additions.
The next read on whether today's reaction breaks from the February pattern will come from how the Q1 revenue figure stacks up against the $111.9M the company posted in Q4, and whether management raises, holds, or trims full-year guidance given the new competitive dynamics around Tyvaso DPI.
See the live data behind this article on ORTEX.
Open MNKD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
